{"id":3056,"date":"2020-12-09T16:29:06","date_gmt":"2020-12-09T21:29:06","guid":{"rendered":"https:\/\/www.wmfc.ca\/?p=3056"},"modified":"2021-01-18T17:23:10","modified_gmt":"2021-01-18T22:23:10","slug":"health-canada-starts-review-of-new-drug-submission-brukinsar-zanubrutinib","status":"publish","type":"post","link":"https:\/\/www.wmfc.ca\/fr\/2020\/12\/09\/health-canada-starts-review-of-new-drug-submission-brukinsar-zanubrutinib\/","title":{"rendered":"Sept. 2020 : Sant\u00e9 Canada entreprend l'examen de BRUKINSA(R) (zanubrutinib)"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"--awb-bg-size:cover;--awb-margin-top:0px;--awb-margin-bottom:0px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-1\"><p>Bien que cela puisse appara\u00eetre comme \"un autre communiqu\u00e9 de presse commercial d'une soci\u00e9t\u00e9 pharmaceutique\", cela va un peu plus loin pour les patients atteints de MW au Canada.  Beigene, ayant obtenu le statut prioritaire aupr\u00e8s de Sant\u00e9 Canada, cherche \u00e0 faire approuver son inhibiteur de BTK de 2\u00e8me g\u00e9n\u00e9ration, le Zanubrutinib (Brukinsa\u00ae), pour le traitement de la MW.  Une fois que l'examen de Sant\u00e9 Canada sera termin\u00e9, et en supposant qu'il soit accept\u00e9, le Zanubrutinib sera sur le m\u00eame pied d'\u00e9galit\u00e9 que l'Ibrutinib pour les patients atteints de MW au Canada.  Beigene fera alors une demande aupr\u00e8s du pCODR (voir notre tr\u00e8s br\u00e8ve explication sur la fa\u00e7on dont les m\u00e9dicaments anticanc\u00e9reux sont approuv\u00e9s et financ\u00e9s au Canada sur notre site Web). <a href=\"\/fr\/questions-canadiennes-courantes-repondues\/\">Page des questions canadiennes<\/a>), en vue d'obtenir une recommandation pour que les provinces l'incluent dans leur liste de m\u00e9dicaments subventionn\u00e9s.  Si tout cela est couronn\u00e9 de succ\u00e8s, cela rendrait enfin un inhibiteur de BTK plus largement disponible pour les Canadiens, et potentiellement pay\u00e9 par les provinces.<\/p>\n<\/div><div class=\"fusion-aligncenter\"><a class=\"fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-1 fusion-button-span-no fusion-button-default-type\" target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/www.businesswire.com\/news\/home\/20200909005119\/en\/BeiGene-Announces-Acceptance-Priority-Review-Health-Canada\"><span class=\"fusion-button-text awb-button__text awb-button__text--default\">Communiqu\u00e9 de presse de Brukinsa concernant l'examen du Zanubrutinib<\/span><\/a><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-3056","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/3056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/comments?post=3056"}],"version-history":[{"count":10,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/3056\/revisions"}],"predecessor-version":[{"id":3547,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/3056\/revisions\/3547"}],"wp:attachment":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/media?parent=3056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/categories?post=3056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/tags?post=3056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}